Innovation Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Innovation Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Innovation Pharmaceuticals: 4 sponsored US clinical trials, none currently recruiting.
Innovation Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ovarian Cancer, with 1 trials.
Upper-quartile sponsor footprint
Innovation Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
NCT04784897
A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
NCT03042702
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
NCT02949388
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
NCT02324335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Therapeutic Areas
How the Innovation Pharmaceuticals early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Ovarian Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Innovation Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Innovation Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Innovation Pharmaceuticals page
4 registered trials is a research-attention snapshot, not an endorsement of Innovation Pharmaceuticals or any single study.
- None of Innovation Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ovarian Cancer is the condition Innovation Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ovarian Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Innovation Pharmaceuticals pipeline card: 4 registered trials from official public datasets.Report a data error.